Cargando…

Screening of selective histone deacetylase inhibitors by proteochemometric modeling

BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dingfeng, Huang, Qi, Zhang, Yida, Zhang, Qingchen, Liu, Qi, Gao, Jun, Cao, Zhiwei, Zhu, Ruixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/
https://www.ncbi.nlm.nih.gov/pubmed/22913517
http://dx.doi.org/10.1186/1471-2105-13-212
_version_ 1782255469932314624
author Wu, Dingfeng
Huang, Qi
Zhang, Yida
Zhang, Qingchen
Liu, Qi
Gao, Jun
Cao, Zhiwei
Zhu, Ruixin
author_facet Wu, Dingfeng
Huang, Qi
Zhang, Yida
Zhang, Qingchen
Liu, Qi
Gao, Jun
Cao, Zhiwei
Zhu, Ruixin
author_sort Wu, Dingfeng
collection PubMed
description BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study. RESULTS: The results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R(2) = 0.9897, Q(test)(2) = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors. CONCLUSIONS: Our best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect.
format Online
Article
Text
id pubmed-3542186
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35421862013-01-11 Screening of selective histone deacetylase inhibitors by proteochemometric modeling Wu, Dingfeng Huang, Qi Zhang, Yida Zhang, Qingchen Liu, Qi Gao, Jun Cao, Zhiwei Zhu, Ruixin BMC Bioinformatics Research Article BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study. RESULTS: The results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R(2) = 0.9897, Q(test)(2) = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors. CONCLUSIONS: Our best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect. BioMed Central 2012-08-22 /pmc/articles/PMC3542186/ /pubmed/22913517 http://dx.doi.org/10.1186/1471-2105-13-212 Text en Copyright ©2012 Wu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wu, Dingfeng
Huang, Qi
Zhang, Yida
Zhang, Qingchen
Liu, Qi
Gao, Jun
Cao, Zhiwei
Zhu, Ruixin
Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title_full Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title_fullStr Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title_full_unstemmed Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title_short Screening of selective histone deacetylase inhibitors by proteochemometric modeling
title_sort screening of selective histone deacetylase inhibitors by proteochemometric modeling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/
https://www.ncbi.nlm.nih.gov/pubmed/22913517
http://dx.doi.org/10.1186/1471-2105-13-212
work_keys_str_mv AT wudingfeng screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT huangqi screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT zhangyida screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT zhangqingchen screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT liuqi screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT gaojun screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT caozhiwei screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling
AT zhuruixin screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling